Role of Thrombin and Thromboxane A2 in Reocclusion Following Coronary Thrombolysis With Tissue-Type Plasminogen Activator.

Proceedings of the National Academy of Sciences of the United States of America- United States

doi 10.1073/pnas.86.19.7585

Full Text

Abstract

Available in

Date

Authors

Publisher

Proceedings of the National Academy of Sciences

Related search

Acute Coronary Thrombolysis With Recombinant Human Tissue-Type Plasminogen Activator: Initial Patency and Influence of Maintained Infusion on Reocclusion Rate

American Journal of Cardiology
Cardiovascular MedicineCardiology
1987English

Coronary Thrombolysis With Facilitated Absorption of Intramuscularly Injected Tissue-Type Plasminogen Activator.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1985English

Thrombolysis of Subarachnoid Clot Using Tissue Plasminogen Activator

Surgery for Cerebral Stroke
1991English

Effects of Vapiprost, a Novel Thromboxane Receptor Antagonist, on Thrombus Formation and Vascular Patency After Thrombolysis by Tissue-Type Plasminogen Activator

British Journal of Pharmacology
Pharmacology
1992English

Thrombin and Plasmin Generation in Patients With Plasminogen or Plasminogen Activator Inhibitor Type 1 Deficiency

Haemophilia
MedicineGeneticsHematology
2019English

Urokinase-Type Plasminogen Activator (PLAU; uPA); Thrombin (F2)

Science-Business eXchange
2010English

Role of Tissue-Type Plasminogen Activator in Remodeling of the Ductus Arteriosus

Circulation Reports
2020English

Tissue-Type Plasminogen Activator: A Role for O-Linked Fucose.

Journal of Clinical Investigation
Medicine
1994English

The Tissue-Type Plasminogen Activator Story

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy